These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 11981429)

  • 21. Simultaneous blockade of co-stimulatory signals, CD28 and ICOS, induced a stable tolerance in rat heart transplantation.
    Guo L; Fujino M; Kimura H; Funeshima N; Kitazawa Y; Harihara Y; Tezuka K; Makuuchi M; Suzuki S; Li XK
    Transpl Immunol; 2003; 12(1):41-8. PubMed ID: 14551031
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Determination of an improved sirolimus (rapamycin)-based regimen for induction of allograft tolerance in mice treated with antilymphocyte serum and donor-specific bone marrow.
    Hale DA; Gottschalk R; Maki T; Monaco AP
    Transplantation; 1998 Feb; 65(4):473-9. PubMed ID: 9500619
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of rapamycin, RS 61443, cyclosporine, and low-dose heparin as treatment for transplant vasculopathy in a rat model of chronic allograft rejection.
    Schmid C; Heemann U; Azuma H; Tilney NL
    Transplant Proc; 1995 Feb; 27(1):438-9. PubMed ID: 7879053
    [No Abstract]   [Full Text] [Related]  

  • 24. Induction of tolerance to an "untolerizable" strain by double-strain intrathymic inoculation in experimental rat cardiac transplantation.
    Mohiuddin MM; Yokoyama H; Reiss GR; DiSesa VJ
    Transplant Proc; 1999; 31(1-2):838-9. PubMed ID: 10083364
    [No Abstract]   [Full Text] [Related]  

  • 25. Synergistic effect of 3M KCl-extracted donor antigens with cyclosporine or cyclosporine/rapamycin to prolong heart allograft survival in rats.
    Hamashima T; Stepkowski SM; Smith S; Kahan BD
    Transplant Proc; 1994 Oct; 26(5):3053-5. PubMed ID: 7940960
    [No Abstract]   [Full Text] [Related]  

  • 26. Nutritional immunomodulation leads to enhanced allograft survival in combination with cyclosporine A and rapamycin, but not FK506.
    Gibson SW; Valente JF; Alexander JW; Custer DA; Li BG; Frede S; Babcock GF; Ogle CK
    Transplantation; 2000 May; 69(10):2034-8. PubMed ID: 10852592
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Portal tolerance in rats: effect of donor cell treatment and timing of administration.
    Tanigawa T; Monden M; Nagano H; Hasuike Y; Gotoh M; Fukuzaki T; Ota H; Yoshida T; Mori T
    Transplant Proc; 1994 Aug; 26(4):1870-1. PubMed ID: 8066608
    [No Abstract]   [Full Text] [Related]  

  • 28. Donor and recipient leukocytes in organ allografts of recipients with variable donor-specific tolerance: with particular reference to chronic rejection.
    Ichikawa N; Demetris AJ; Starzl TE; Ye Q; Okuda T; Chun HJ; Liu K; Kim YM; Murase N
    Liver Transpl; 2000 Nov; 6(6):686-702. PubMed ID: 11084053
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of perioperative portal venous administration of donor lymphocytes on survival of rat cardiac allografts and renal grafts of the mongrel dog.
    Hirakawa K; Yoshimura N; Lee CJ; Yasui H; Ohsaka Y; Hamashima T; Oka T
    Transplant Proc; 1993 Feb; 25(1 Pt 1):346-7. PubMed ID: 8438328
    [No Abstract]   [Full Text] [Related]  

  • 30. Donor leukocytes combined with delayed immunosupressive drug therapy prolong limb allograft survival.
    Matsumoto T; Kanatani T; Lanzetta M; Fujioka H; Kurosaka M; McCaughan GW; Bishop GA
    Transplant Proc; 2005 Dec; 37(10):4630-3. PubMed ID: 16387186
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Progressive change in tolerance mechanisms after withdrawing combination immunosuppression with cyclosporine and rapamycine or leflunomide.
    Lin Y; Waer M
    Transplant Proc; 1996 Dec; 28(6):3159. PubMed ID: 8962224
    [No Abstract]   [Full Text] [Related]  

  • 32. Analysis of donor-specific unresponsiveness to rat allografts by nondepleting anti-CD4 monoclonal antibody (RIB 5/2) plus donor antigen.
    Motoyama K; Lehmann M; Flye MW
    Transplant Proc; 1999; 31(1-2):1237-8. PubMed ID: 10083552
    [No Abstract]   [Full Text] [Related]  

  • 33. Intrathymic injection of alloantigen may lead to hyperacute rejection and prolonged graft survival of heart allografts in the rat.
    de Bruin RW; van Rossum TJ; Scheringa M; Bonthuis F; IJzermans JN; Marquet RL
    Transplantation; 1995 Nov; 60(9):1061-3. PubMed ID: 7491686
    [No Abstract]   [Full Text] [Related]  

  • 34. Selective immunosuppression induces tolerance after liver transplantation: an immunohistochemical and cytofluorographic analysis of the graft and recipient immune system.
    Gassel HJ; Greiner A; Eckstein V; Timmermann W; Gassel AM; Thiede A
    Transplant Proc; 1997; 29(1-2):1163. PubMed ID: 9123253
    [No Abstract]   [Full Text] [Related]  

  • 35. Preventing allograft rejection with CTLA4IG: effect of donor-specific transfusion route or timing.
    Bolling SF; Lin H; Wei RQ; Turka LA
    J Heart Lung Transplant; 1996 Sep; 15(9):928-35. PubMed ID: 8889989
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Host CD40 ligand deficiency induces long-term allograft survival and donor-specific tolerance in mouse cardiac transplantation but does not prevent graft arteriosclerosis.
    Shimizu K; Schönbeck U; Mach F; Libby P; Mitchell RN
    J Immunol; 2000 Sep; 165(6):3506-18. PubMed ID: 10975872
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4Ig plus donor-specific transfusion.
    Lin H; Bolling SF; Linsley PS; Wei RQ; Gordon D; Thompson CB; Turka LA
    J Exp Med; 1993 Nov; 178(5):1801-6. PubMed ID: 8228826
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A novel CD154 monoclonal antibody in acute and chronic rat vascularized cardiac allograft rejection.
    Yuan X; Dong VM; Coito AJ; Waaga AM; Salama AD; Benjamin CD; Sayegh MH; Chandraker A
    Transplantation; 2002 Jun; 73(11):1736-42. PubMed ID: 12084995
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dependence of acquired systemic tolerance to rat islet allografts induced by intrathymic soluble alloantigens on host responsiveness, MHC differences, and transient immunosuppression in the high responder recipient.
    Fiedor P; Jin MX; Hardy MA; Oluwole SF
    Transplantation; 1997 Jan; 63(2):279-83. PubMed ID: 9020331
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Donor leukocytes combine with immunosuppressive drug therapy to prolong limb allograft survival.
    Kanatani T; Lanzetta M; Owen E; Matsumoto T; Fujioka H; Kurosaka M; McCaughan GW; Bishop GA
    Transplant Proc; 2005 Jun; 37(5):2382-4. PubMed ID: 15964421
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.